As the use of EGFR and multikinase inhibitors increases, offering treatment benefits to patients diagnosed with a variety of tumor types, APs should anticipate dermatologic toxicities and treat patients in a proactive, evidence-based approach. This evidence concerns the gene EGFR and neoplasm.